

Defeside-500

Deferasirox Tablets IP 500 mg



Effective Iron Chelation
Deferasirox effectively reduces iron overload by chelating excess iron.¹



Once-Daily Dosing
Convenient once-daily dosing improves patient adherence and compliance.²



Improves Iron Balance
Significantly reduces serum ferritin levels and total body iron burden.³



Well Tolerated
Generally well tolerated with a manageable safety profile.⁴



Renal Safety
Minimal renal impact when used appropriately with regular monitoring.⁵



Enhances Quality of Life
Reduces complications of iron overload and improves overall quality of life.⁶

INDICATIONS



Thalassemia



Sickle Cell Disease



Transfusion Dependent Anemias



Myelodysplastic Syndromes



Chronic Iron Overload



Other Transfusion Related Conditions

REFERENCES

- Cappellini MD, Cohen A, Piga A, et al. Efficacy and safety of deferasirox in iron-overloaded patients with thalassemia. *Blood*. 2006;107(9):3455-3462.
- Vichinsky EP, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload. *Blood*. 2007;109(10):4582-4588.
- Piga A, Galanello R. For the EPIC Study Investigators. Randomized phase II study of deferasirox (JCL670) in thalassaemia major patients with iron overload. *Br J Haematol*. 2006;135(5):662-669.
- Racovic V, Krznik I, Djordjevic V, et al. Safety and tolerability of deferasirox in children and adolescents with transfusional iron overload. *Pediatr Blood Cancer*. 2011;57(6):1025-1031.
- Aydinok Y, Kattanias A, Cappellini MD, et al. Renal safety of deferasirox: results from clinical trials and post-marketing surveillance. *Blood Cells Mol Dis*. 2012;48(5):166-174.
- Taher AT, Porter J, Vignakesit V. Deferasirox for the treatment of iron overload. *Ther Clin Risk Manag*. 2007;3(5):959-969.